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Abstract Shakuyakukanzoto (SKT) is a kampo medicine
composed of equal proportions of Glycyrrhizae radix
(G. radix) and Paeoniae radix (P. radix). A double-blind
study reported that SKT significantly ameliorated painful
muscle cramp in cirrhosis patients without the typical
severe side effects of muscle weakness and central nervous
system (CNS) depression. Previous basic studies reported
that SKT and its active components induced relaxation by a
direct action on skeletal muscle and that SKT did not de-
press CNS functions; however, why SKT has a lower in-
cidence of muscle weakness remains unknown. In the
present study, we investigated which components are ab-
sorbed into the blood of rats after a single oral adminis-
tration of SKT to identify the active components of SKT.
We also investigated the effects of SKT and its components
on the twitch contraction induced by physiological Ca2?
release. Our study demonstrated that SKT and five G. radix
isolates, which are responsible for the antispasmodic effect
of SKT, did not inhibit the twitch contraction in contrast to
dantrolene sodium, a direct-acting peripheral muscle re-
laxant, indicating that the mechanisms of muscle contrac-
tion of SKT and dantrolene in skeletal muscle differ. These
findings suggest that SKT does not reduce the contractile
force in skeletal muscle under physiological conditions,
i.e., SKT may have a low risk of causing muscle weakness
in clinical use. Considering that most muscle relaxants and
anticonvulsants cause various harmful side effects such as
weakness and CNS depression, SKT appears to have a
benign safety profile.
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Introduction
Most relaxants or anticonvulsants commonly work sys-
temically against the symptoms of muscle pain and spasms;
their therapeutic effects, however, are not always sufficient.
Furthermore, these drugs produce adverse effects such as
muscle weakness and central nervous system (CNS) de-
pression, including dizziness and drowsiness [1, 2], which
impair the quality of life of patients.
Shakuyakukanzoto (SKT) is a kampo medicine com-
posed of equal proportions of Glycyrrhizae radix
(G. radix) and Paeoniae radix (P. radix). Clinical studies
to date have reported that SKT significantly ameliorates
muscle symptoms in patients with a broad array of un-
derlying diseases. SKT has shown immediate efficacy on
painful muscle cramps induced by liver cirrhosis [3],
diabetic neuropathy [4], and hemodialysis [5, 6]. In ad-
dition, SKT has been found to ameliorate the myalgia
and arthralgia induced by combination paclitaxel and
carboplatin chemotherapy [7–9]. It is well known that a
habitual daily intake and excessive daily ingestion of
G. radix induce pseudoaldosteronism, which is charac-
terized by hypokalemia and rhabdomyolysis [10]. How-
ever, a double-blind study in which the patients with
liver cirrhosis received a daily dose of 7.5 g SKT in
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three divided doses for 2 weeks reported that there was
no significant difference in the frequencies of adverse
reactions between SKT and placebo groups, and that
SKT did not induce severe adverse effects such as
muscle weakness and CNS depression [3]. Other clinical
studies have further reported that no adverse events were
observed during treatment with SKT [5–7, 9].
A recent study found that SKT (intraduodenal admin-
istration, i.d.) and six G. radix isolates (intravenous ad-
ministration, i.v.) [glycyrrhetic acid (GA), liquiritigenin
(LQG), liquiritin apioside (LQA), isoliquiritigenin (ILQG),
isoliquiritin apioside (ILQA), and glycycoumarin (GCM)]
act directly on skeletal muscles to inhibit tetanic contrac-
tions with a mechanism of action outside the CNS in an
experimental cramp model [11]. Moreover, a basic phar-
macological study revealed that SKT (2 g/kg) does not
affect general behavior nor significantly change the func-
tions of CNS, respiratory, cardiovascular, gastrointestinal,
or renal systems in normal animals [12]. However, why
SKT treatment has a lower incidence of muscle weakness,
which is known as a typical adverse effect of muscle re-
laxants, remains to be revealed.
Moreover, since the pharmacokinetic profiles of active
components in SKT after oral administration have not been
adequately investigated, it remains unclear whether those
constituents are actually absorbed into the systemic circu-
lation to exert the effects on skeletal muscle. In the present
study, therefore, we investigated which components are
absorbed into the systemic circulation after a single oral
administration of SKT to rats first. Secondly, we investi-
gated the effects of SKT and its absorbed components on
twitch contractions induced by electrical stimulation of
intact skeletal muscle cell. Dantrolene sodium, a well-
known direct-acting peripheral muscle relaxant, was used
as a control drug.
Materials and methods
Animals
Male Sprague–Dawley and Wistar rats were purchased
from Japan SLC (Shizuoka). Sprague–Dawley rats were
used to identify the absorbed components of SKT in ac-
cordance with previous studies [14–16]. Because a previ-
ous study reported that isometric training induced muscle
hypertrophy of the gastrocnemius in Sprague–Dawley rats
[17], the effects of SKT and its absorbed components on
electrically induced muscle contraction were studied using
Wistar rats. All animal experiments were conducted in
accordance with the guidelines for animal use and care
established by the Laboratory Animal Committee, Tsumura
& Co. (Tokyo).
SKT and its components
The spray-dried powder extracts of SKT (nos. 280068010,
322098500) were supplied by the Ibaraki Plant, Tsumura &
Co. SKT was composed of equal proportions of G. radix
(root and stolon of Glycyrrhiza uralensis Fischer, Legu-
minosae) and P. radix (root of Paeonia lactiflora Pallas,
Paeoniaceae), which was manufactured in compliance with
the Japanese Pharmacopoeia (Sixteenth Edition, JP16)
under good manufacturing practice (GMP). Therefore, the
quality and authenticity of SKT extract powder were as-
sured. SKT was prepared by decocting G. radix and
P. radix in boiling water for 60 min. The extraction yield of
SKT was approximately 21 %. The voucher specimens
have been deposited at the Ibaraki Plant, Tsumura & Co.
The extraction procedure and chemical profiles of SKT
have been reported in a previous study [11]. Briefly, 1.0 g
of SKT was extracted with 20 mL of 75 % methanol for
30 min for high-performance liquid chromatography-ul-
traviolet (HPLC-UV) analysis. Chemical profiles of SKT
were investigated using the three-dimensional HPLC fin-
gerprint method.
The powdered extracts of GA, liquiritin (LQ), LQG,
LQA, isoliquiritin (ILQ), ILQG, ILQA, GCM, paeoniflorin
(PAE), and albiflorin (ALB) with purities high enough for
use in biological studies were supplied by the Kampo
Formulations Development Center, Tsumura & Co.
Drug administration and sampling for pharmacokinetics
investigation
Male Sprague–Dawley rats (7 weeks old, n = 4–5/time
point) were housed for 5 days in a controlled environment
with free access to water and normal chow prior to ex-
periments. SKT was suspended in distilled water at 10 mL/
kg. After a 15–17-h fast, rats received a single oral gavage
dose of 1 g/kg. Blood was collected from the ventral aorta
under isoflurane anesthesia at 0 (pre), 5, 15, 30 min, 1, 2, 4,
8, 10, 12, 24, 36, and 48 h after administration. Hepar-
inized blood samples were immediately centrifuged to
separate the plasma. All plasma samples were stored at
-80 C until analysis.
Quantitative determination of plasma concentrations
We determined the plasma concentrations of eight com-
ponents of G. radix (GA, LQ, LQG, LQA, ILQ, LQG,
ILQA, and GCM) and two components of P. radix (PAE
and ALB) in rat plasma after a single oral administration of
SKT. GA, LQ, LQG, LQA, ILQ, ILQG, ILQA, GCM,
PAE, and ALB were dissolved in methanol and serially
diluted with 50 % aqueous methanol to make the working
solutions. Calibration standards were prepared by spiking
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pooled blank rat plasma (Sprague–Dawley rats, Japan
SLC) with the working solutions. Niflumic acid (Sigma-
Aldrich, St. Louis, MO, USA) or digoxin (Alfa Aesar,
Heysham, UK) was dissolved in methanol, diluted with
50 % aqueous methanol, and used as an internal standard
(IS) for each analytical method.
The plasma concentrations of all components were deter-
mined using liquid chromatography-tandem mass spec-
trometry (LC–MS/MS). The instrument was composed of a
1260 Infinity LC System (Agilent Technologies, Santa Clara,
CA, USA) and a QTRAP 5500 system (AB SCIEX, Fram-
ingham, MA, USA). Samples were prepared by protein pre-
cipitation with acetonitrile, and 5-lL aliquots were applied to
the analytical column. Mass spectrometry detections were
operated using an electrospray ionization (ESI) interface in
negative ion mode by multiple-reaction monitoring (MRM).
The calibration curve ranges (ng/mL)were 0.05–10 forGCM,
0.1–10 for ILQ, 0.1–100 for ALB, 0.5–10 for LQ, LQG,
ILQG, LQA, and ILQA, 0.5–100 for PAE, and 2.0–1000 for
GA. The analytical methods are summarized in Table 1.
In vivo experiment on skeletal muscle
Male Wistar rats (250–300 g, n = 4–6/group) were used
for in vivo contractile experiments. Experimental proce-
dures were conducted as reported in a previous paper [11].
Briefly, the tibial nerve, which innervates the gastrocne-
mius muscle, on the left leg was exposed and transected on
the spinal side for complete elimination of the spinal reflex
in rats under urethane anesthesia (1.08 g/kg, i.p., Sigma-
Aldrich). The isolated tibial nerve was connected to an
electric stimulator (Nihon Kohden, Tokyo) via an isolator
(Physio-Tech, Tokyo). To evoke twitch contractions, a 0.3-
ms square-wave electric pulse (3 V) was applied to the
tibial nerve. The contractile responses of the gastrocnemius
muscle were detected by a force transducer (Nippon
Avionics, Tokyo) connected to the Achilles tendon at 5, 10,
15, 20, 30, 40, 50, and 60 min after the administration of
test solutions. The body temperature of rats was maintained
at 37–37.5 C during the experiments.
SKTwas suspended in distilledwater and intraduodenally
administered to rats at doses of 0.5 or 1 g/kg through an
indwelling catheter. LQ, LQG, LQA, ILQ, ILQG, ILQA, and
GCM were dissolved in a mixture of ethanol, propylene
glycol, and 0.9 % saline solution prepared in a ratio of 1:4:5.
GA was dissolved in a mixture of ethanol, 25 % ammonia
water, and 0.9 % saline solution prepared in a ratio of
1:0.05:8.95. Eight components [(LQ, LQG, LQA, ILQ,
ILQG, ILQA, 20 lmol/kg), GCM (2.7 and 27 lmol/kg), and
GA (7 and 35 lmol/kg)] were administered i.v. to rats. The
rats received dantrolene sodium (Sigma-Aldrich, St. Louis,
MO, USA) at doses of 10 and 30 mg/kg (i.d.).
In vitro experiment on skeletal muscle
The left hemidiaphragm of male Wistar rats (300–400 g)
was isolated and immediately mounted together with the
phrenic nerve in a dissecting dish. Small muscle strips from
the hemidiaphragm containing the innervating phrenic
nerve were prepared and perfused with Krebs–Ringer bi-
carbonate buffer (113 mM NaCl, 5.0 mM KCl, 1.4 mM
CaCl2, 0.9 mM MgSO4, 1.2 mM NaH2PO4, 25 mM
NaHCO3, 11.5 mM glucose) oxygenated with 95 % O2 and
5 % CO2. Platinum electrodes were placed over the di-
aphragm muscles. A direct twitch response was elicited by
stimulating the muscle supramaximally with 0.2-Hz rect-
angular pulses of 0.5-ms duration and recorded with an
isometric transducer (Nihon Kohden).
Table 1 Summary of analytical determination methods for 10 components of SKT
Method HPLC condition MRM transition (m/z) Target component
Q1 Q3
1 YMC-Pack ODS-AQ (50 9 2.0 mm, 3 lm)a 469.3 425.4 GA
Gradient of 45–80 % B, over 5 min, 0.2 mL/min 281.0 237.0 Niflumic acid (IS)
A: 10 mM NH4OAc in water, B: MeCN
2 Atlantis dC18 (100 9 2.1 mm, 3 lm)b 417.1 255.1 LQ, ILQ
Gradient of 10–85 % B over 17 min, 0.2 mL/min 255.0 119.0 LQG, ILQG
A: 10 mM NH4OAc in water, B: MeCN 549.1 255.0 LQA, ILQA
366.9 308.9 GCM
780.4 650.6 Digoxin (IS)
3 Atlantis dC18 (100 9 2.1 mm, 3 lm)b 479.0 121.0 PAE, ALB
Isocratic solution of A and B (82:18), 0.2 mL/min
A: 0.2 % AcOH in water, B: 0.2 % AcOH in MeCN
a YMC (Kyoto)
b Waters (MA, USA)
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SKT was suspended in Krebs–Ringer bicarbonate buffer
at doses of 10-5–10-3 g/mL.
Statistical analysis
All analytical data were processed using Analyst software,
version 1.6.2 (AB SCIEX). The pharmacokinetics (PK)
parameters, including peak plasma concentration (Cmax),
time to Cmax (Tmax), elimination half-life (T1/2), area under
the curve (AUClast), and mean residence time (MRT), were
calculated by non-compartmental analysis for sparse sam-
pling using Phoenix WinNonlin software, version 6.3
(Certara, St. Louis, MO, USA). The calculated parameters
are expressed as the mean or mean ± standard error of the
mean (SE).
The results of experiments on skeletal muscle are ex-
pressed as mean ± SE. Changes in twitch height are ex-
pressed as a percentage of the original twitch height prior
to the administration of each agent. Data were analyzed
using one-way analysis of variance (ANOVA), followed by
Student’s t-test or Dunnett’s test. p-Values of\0.05 were
considered to be statistically significant.
Results
Pharmacokinetics study
Plasma concentration–time profiles of the components after
a single oral administration of SKT are presented in Figs. 1
and 2. The PK parameters are shown in Table 2.
A previous study reported that orally administered gly-
cyrrhizin (GL) was absorbed after being extensively me-
tabolized to its aglycone, GA, by intestinal bacteria [13].
After SKT administration, GA was absorbed slowly,
reached its maximum concentration at 8 h, and remained in
the blood longer than other components.
LQ, ILQ, LQA, and ILQA had similar PK profiles,
showing rapid absorption with a Tmax of 0.25 h and an
elimination half-life within 3 h. Plasma concentration–time
course curves of two flavonoid aglycones (LQG and ILQG)
exhibited bimodal kinetics with peaks at 0.25 and 8 h post
dose. These phenomena were consistent with the findings of
previous studies [14, 15]. Flavonoid glycosides (LQ, LQA,
ILQ, and ILQA) have been found to be converted to their
aglycones inside an organism [16]. LQGand ILQG remained
in the blood for a prolonged period (10–12 h) due to delayed
absorption of biotransformed LQG and ILQG. Plasma GCM
was detected in only two rats at 0.25 and 4 h, respectively, at
concentrations of less than 0.1 ng/mL (data not shown).
PAE and ALB were rapidly absorbed with peak plasma
levels being reached within 1 h and eliminated rapidly with
an approximate T1/2 of 1.5 h.
Effects of SKT on skeletal muscle
The effects of SKT and dantrolene on rat gastrocnemius
muscle are shown in Fig. 3a. SKT (0.5, 1 g/kg, i.d.) did not
inhibit twitch contractions induced by electrical stimula-
tion. In contrast, dantrolene (10, 30 mg/kg, i.d.) reduced
twitch contractions by 43–72 % between 5 and 60 min
after administration. There was no significant dose-de-
pendent inhibitory effect of dantrolene. GCM at the highest
dose tested (27 lmol/kg, i.v.) exhibited significant inhibi-
tion (17 % of the twitch amplitude) at 10 min after ad-
ministration (Fig. 3b). The others, including flavonoids and
triterpenoids, did not show inhibitory effects (Table 3). In
in vitro experiments, SKT did not significantly inhibit the
twitch response elicited by direct stimulation at doses of
10-5–10-3 g/mL (Table 4).
Discussion
Studies of the pharmacological mechanism of SKT in
skeletal muscle have focused on two major components of
G. radix and P. radix, GL and PAE, respectively. Basic
pharmacological studies have shown that GL inhibits
Ca2?-activated K? channels, that PAE blocks intracellular
Ca2? movement, and that the combination of GL and PAE
displays synergistic effects on antispasmodic activity at the
myoneural junction [18–20]. In addition, six components of
G. radix (GA, LQG, LQA, ILQG, ILQA, and GCM) were
reported to significantly inhibit tetanic contractions after
intravenous administration in rats [11]. Two components of
P. radix (PAE and ALB) were found to have a significant
antinociceptive effect via spinal a2-adrenoceptor activation
[21, 22], although these components probably do not in-
hibit any contraction elicited by electrical stimulation be-
cause P. radix does not show a significant antispasmodic
effect [11].
In our study, LQG, LQA, ILQG, ILQA, PAE, and ALB
showed rapid absorption (Tmax 0.25–1 h) after a single oral
administration of 1 g/kg SKT to rats. GA was absorbed
slowly, but it was detectable in plasma immediately after
administration. Moreover, a clinical study previously re-
ported that SKT alleviated painful muscle cramp within
15 min after oral administration [5]. Plasma concentration–
time profiles of these components were clearly correlated
with the rapid onset of the antispasmodic and analgesic
effects of SKT on skeletal muscle in humans.
GA, LQG, and ILQG remained in the blood for a pro-
longed period. Symptoms of pseudoaldosteronism, such as
increased blood pressure and edema, were observed in a
double-blind study, although there were no significant
differences in the frequency of adverse reactions between
SKT and placebo groups. A study has also reported that
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3-monoglucuronyl-glycyrrhetinic acid (3MGA) caused
G. radix-induced pseudoaldosteronism [23]. Isbrucker and
Burdock [24] reported that orally administered GL was
hydrolyzed to 3MGA first and then to GA by intestinal
bacteria. In the present study, GA showed very slow
elimination from the systemic circulation, which suggests
the possibility that repeated SKT administration increases
the blood exposure level of GA. Therefore, it is necessary
to exercise caution during multiple administration of SKT
or combined application of other medicine containing
G. radix or GL.
In the present study, we investigated the effects of SKT
and its components on skeletal muscle contraction under
physiological conditions in vivo and in vitro. SKT exhib-
ited no inhibitory effects on electrically induced twitch
contractions in a rat gastrocnemius muscle model in vivo,
whereas dantrolene, a direct-acting peripheral muscle re-
laxant, robustly inhibited twitch contractions. A 1-g/kg
dose of SKT is sufficient to inhibit tetanic contraction [11].
We also found that five G. radix isolates (GA, LQG, LQA,
ILQG, and ILQA), which were responsible for the an-
tispasmodic effect of SKT, and two flavanone glycoside
Fig. 1 Plasma concentration
profiles of 7 components of
G. radix after a single oral
administration of SKT at a dose
of 1 g/kg. Data are expressed as
mean ? SD (n = 4–5 for each
time point)
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forms (LQ and ILQ) exhibited no inhibitory effects on
twitch contractions. Dantrolene concentrations (10 and
30 mg/kg) were set according to a previous study [25]. Lee
et al. [11] reported that dantrolene did not inhibit muscle
performance up to 90 mg/kg in the rotarod test in rats. In
the present study, dantrolene robustly inhibited twitch
contraction irrespective of concentration. This result is at-
tributed to the fact that this experimental rat model ex-
hibited greater sensitivity than the rotarod test reported in a
previous study [11]. In addition, SKT did not show any
inhibition, even at high concentrations, in an in vitro study.
Notably, the majority of these results are contradictory to
Fig. 2 Plasma concentration profiles of 2 components of P. radix after a single oral administration of SKT at a dose of 1 g/kg. Data are
expressed as mean ? SD (n = 4–5 for each time point)
Table 2 Pharmacokinetics
parameters of SKT components
after a single oral administration
of SKT
The results are expressed as the
mean or mean ± SE (n = 4–5
for each time point)
Compound Cmax (ng/mL) Tmax (h) AUClast (hng/mL) T1/2 (h) MRTlast (h)
GA 1400 ± 181 8.00 15200 ± 1360 3.50 10.0
LQ 30.9 ± 4.70 0.250 37.2 ± 2.32 1.94 1.32
LQG 9.35 ± 3.01 8.00 50.0 ± 9.61 0.978 6.37
LQA 9.08 ± 1.43 0.250 27.1 ± 1.40 2.65 2.21
ILQ 7.47 ± 1.71 0.250 8.48 ± 0.621 1.61 1.50
ILQG 4.31 ± 0.866 0.250 19.3 ± 1.82 1.02 5.27
ILQA 1.18 ± 0.201 0.250 1.13 ± 0.138 0.469 0.723
PAE 36.0 ± 4.89 0.500 141 ± 7.43 1.48 2.50
ALB 4.88 ± 0.952 1.00 18.4 ± 1.09 1.55 2.51
Fig. 3 Effects of SKT (i.d.) and
dantrolene sodium (i.d.) (a) and
glycycoumarin (i.v.) (b) on
electrically induced twitch
contractions in a rat
gastrocnemius muscle model.
Each value represents the
mean ± SE of 4–6 rats.
*p\ 0.05, **p\ 0.01
compared with the vehicle
group (Dunnett’s t-test)
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those of previous reports [11], i.e., SKT appeared to act
specifically against tetanus rather than twitch, whereas
dantrolene inhibited both tetanus and twitch contractions.
GCM (27 lmol/kg) at a higher concentration showed a
transient inhibitory effect on the twitch contraction. Qiao
et al. [15] reported that GCM was eliminated very quickly
from the blood after oral administration of G. radix water
extract (5 g/kg) in rats. Although GCM showed an imme-
diate inhibitory effect on twitch contraction at 10 min after
intravenous administration, we assumed that this effect
disappeared with the decrease of the GCM level in the
blood. When 1 g/kg of SKT was orally administered, we
found that GCM was barely detectable in rat plasma.
Therefore, we suggest that SKT did not significantly inhibit
twitch contraction after oral administration. The observed
plasma GCM levels after oral administration of SKT in
humans are appealing, and a subsequent human PK study is
currently in progress.
Ryanodine receptor (RyR)-mediated Ca2? release from
the sarcoplasmic reticulum (SR) is a crucial process in
skeletal muscle contraction [26]. Previous studies reported
that intracellular Ca2? release mediated by RyR from the
SR was involved in two different RyR1 opening modes,
Ca2?-induced Ca2? release (CICR) and physiological Ca2?
release [27–29]. Physiological Ca2? release in skeletal
muscle is caused by depolarization of the t-tubule mem-
brane, whereas CICR is elicited by successive activation of
calcium release from intracellular Ca2? stores. In con-
tractions induced by electrical stimulation, twitch and te-
tanus reflect physiological Ca2? release and CICR,
respectively, in their mechanisms of Ca2? mobilization. In
our study, SKT or its seven components did not inhibit
twitch contractions, indicating that they selectively inhib-
ited only CICR rather than physiological Ca2? release. We
suggest that this is the reason for SKT causing a lower
incidence of muscle weakness in clinical use, although
SKT is effective in reducing muscle spasms. RyR is rec-
ognized as the channel responsible for both CICR and
physiological Ca2? release, and it opens for each different
mode, depending on the Ca2? concentration around the SR
or on the information to be transferred from the potential
sensor of the t-tubule. Under physiological conditions, it is
difficult to evoke CICR because Ca2? cannot completely
open the RyR channels. Therefore, to elucidate the
mechanism of SKT, which selectively inhibited only
CICR, it is necessary to measure the Ca2? release from the
SR using the system to induce CICR. In future, we are
planning to study the inhibitory effect of SKT for caffeine,
which induces CICR, or for clofibric acid, which induces
Ca2? release similar to physiological Ca2? release [27], in
skinned fibers.
Dantrolene depresses excitation–contraction coupling in
skeletal muscle by inhibiting both CICR [30] and physio-
logical Ca2? release [31–34]; this is consistent with our
results on dantrolene. At the molecular level, the dan-
trolene-binding site is located in the Leu590–Cys609 region
of the N-terminal portion of the RyR1 domain switch [35].
Dantrolene or its analog has been found to stabilize a
synthetic domain peptide (DP4) of RyR to block CICR
from the SR or suppress the rate of RyR opening, respec-
tively [35, 36]. It is an important issue for future study to
determine whether SKT components bind to the same site
as dantrolene; this may clarify the difference between
dantrolene and SKT.
Table 3 Effects of flavonoids and triterpenoids on electrically induced twitch in rat gastrocnemius muscle
Treatment Concentration 0 min 5 min 10 min 15 min 20 min 30 min 60 min
Vehicle (lmol/kg) 102.1 ± 4.0 85.6 ± 4.5 80.2 ± 4.3 87.6 ± 11.1 82.6 ± 9.1 70.7 ± 6.4 68.5 ± 8.0
LQ 20 98.1 ± 3.2 91.6 ± 3.2 86.2 ± 3.7 83.0 ± 5.1 73.5 ± 8.5 70.4 ± 3.9 69.4 ± 3.4
ILQ 20 109.5 ± 27.2 92.5 ± 21.9 77.4 ± 6.8 77.8 ± 11.5 73.8 ± 13.1 67.7 ± 8.6 69.5 ± 10.8
LG 20 86.0 ± 3.4 77.1 ± 1.7 73.8 ± 2.6 67.6 ± 2.4 61.1 ± 2.8 56.9 ± 2.8 58.2 ± 5.5
ILG 20 106.0 ± 4.3 109.7 ± 10.0 100.1 ± 9.7 72.5 ± 8.1 70.7 ± 5.9 66.5 ± 9.3 69.6 ± 7.2
LQA 20 97.0 ± 5.7 86.2 ± 2.4 80.7 ± 4.1 72.0 ± 4.2 67.9 ± 4.2 66.5 ± 6.1 61.1 ± 3.7
ILQA 20 99.7 ± 6.4 87.9 ± 5.6 76.7 ± 2.0 69.8 ± 1.3 68.8 ± 2.8 64.6 ± 1.8 67.0 ± 3.5
GA 7 106.4 ± 6.4 94.5 ± 4.3 87.0 ± 4.6 80.1 ± 3.9 76.6 ± 5.3 74.0 ± 6.3 73.0 ± 8.0
GA 35 99.4 ± 7.1 84.6 ± 6.0 79.6 ± 5.2 78.8 ± 7.3 71.9 ± 6.3 67.4 ± 5.2 67.6 ± 6.3
Each value represents the mean ± SE of 3–6 rats. No statistically significant differences were found (Student’s t-test)
Table 4 Effects of SKT on electrically induced twitch in rat phrenic
nerve-hemidiaphragm muscle preparation
Concentration (g/mL)
1 9 10-5 1 9 10-4 1 9 10-3
Control 102.5 ± 5.3 111.3 ± 11.2 104.5 ± 9.6
SKT 104.5 ± 5.6 106.6 ± 8.3 96.1 ± 4.5
Each value represents the mean ± SE of 8 rats. No statistically sig-
nificant differences were found (Student’s t-test)
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In summary, our findings indicated that SKT (up to 1 g/
kg) and five G. radix isolates (GA, LQG, LQA, ILQG, and
ILQA), which were responsible for the immediate an-
tispasmodic efficacy of SKT, had no inhibitory effect on
twitch tension caused by physiological Ca2? release. This
was in contrast to the effects of dantrolene, indicating that
the mechanisms of muscle contraction of SKT and dan-
trolene in skeletal muscle differ. These findings suggest
that SKT does not reduce the contractile force in skeletal
muscle under physiological conditions, i.e., SKT may have
a low risk of causing muscle weakness in clinical use. To
prevent pseudoaldosteronism, it is necessary to exercise
caution in the repeated administration of SKT or combined
application of other medicine containing G. radix or GL.
However, considering that most muscle relaxants and an-
ticonvulsants cause various harmful side effects such as
weakness and CNS depression, SKT appears to have a
benign safety profile.
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